Previous 10 | Next 10 |
Positive INTERCEPT-AD Phase 1 trial results announced in July 2023 demonstrate ACU193’s potential as a differentiated antibody for the treatment of early Alzheimer’s disease Cash, cash equivalents and marketable securities of $172.2 million as of June 30, 2023, bolstered by ...
CHARLOTTESVILLE, Va. and CARMEL, Ind., Aug. 01, 2023 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) (“Acumen” or the “Company”), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligo...
2023-07-19 06:45:12 ET Clinical-stage biopharmaceutical company, Acumen Pharmaceuticals ( NASDAQ: ABOS ) prices an upsized underwritten public offering of ~16.77M shares at a price to the public of $7.75 per share. Gross proceeds are expected to be ~$130M. The offering...
CHARLOTTESVILLE, Va. and CARMEL, Ind., July 18, 2023 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (“Acumen”) (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets soluble amyloid beta oligomers (AβOs) for the treatment of A...
2023-07-18 11:32:07 ET Shares of Acumen Pharmaceuticals (NASDAQ: ABOS) were down more than 16% at 11 a.m. on Tuesday after the company announced a public stock offering. The company's shares are still up more than 50% so far this year. The clinical-stage biotech company focu...
2023-07-18 08:34:40 ET Summary Positive topline results released from phase 1 INTERCEPT-AD study, which used ACU193 for the treatment of patients with early AD. The global market for Alzheimer's disease treatments is expected to rise past $13 billion by 2030. There was statist...
2023-07-17 17:27:38 ET Acumen Pharmaceuticals ( NASDAQ: ABOS ) has proposed an underwritten public offering of its common stock to raise $100 million, the company said Monday. All of the shares to be sold in the offering are to be sold by the company. The underwr...
CHARLOTTESVILLE, Va. and CARMEL, Ind., July 17, 2023 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets soluble amyloid beta oligomers (AβOs) for the treatment of Alzheimer’s dis...
2023-07-17 10:07:51 ET Gainers: ProMIS Neurosciences ( PMN ) +149% . BridgeBio Pharma ( BBIO ) +62% . Acumen Pharmaceuticals ( ABOS ) +60% . Healthcare Triangle ( HCTI ) +42% . argenx ( ARGX ) +30% . Losers: Apellis P...
2023-07-17 10:00:46 ET Shares of Acumen Pharmaceuticals ( NASDAQ: ABOS ) rallied more than 60% in early trading Monday in the wake of the release of positive data from a Phase 1 clinical trial for its Alzheimer's disease drug candidate ACU193. Acumen shares opened at a $6.11, re...
News, Short Squeeze, Breakout and More Instantly...
Acumen Pharmaceuticals Inc. Company Name:
ABOS Stock Symbol:
NASDAQ Market:
Acumen Pharmaceuticals Inc. Website:
NEWTON, Mass., July 28, 2024 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers (AβOs) for the treatment of Alzheimer’s disease (AD), to...
NEWTON, Mass., July 11, 2024 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers (AβOs) for the treatment of Alzheimer’s disease (AD), to...
Announced initiation of ALTITUDE-AD, a Phase 2 study to investigate sabirnetug (ACU193) for the treatment of early Alzheimer’s disease, in May 2024 Initiation of a Phase 1 study to support a subcutaneous dosing option of sabirnetug expected in mid-2024 Cash, cash equivalent...